Jinghai J Xu
Overview
Explore the profile of Jinghai J Xu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
540
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xu J
Front Pharmacol
. 2015 Oct;
6:191.
PMID: 26441648
Incorporating phenotypic screening as a key strategy enhances predictivity and translatability of drug discovery efforts. Cellular imaging serves as a "phenotypic anchor" to identify important toxicologic pathology that encompasses an...
2.
Michaud N, Jani J, Hillerman S, Tsaparikos K, Barbacci-Tobin E, Knauth E, et al.
MAbs
. 2012 Sep;
4(6):710-23.
PMID: 23007574
The c-Met proto-oncogene is a multifunctional receptor tyrosine kinase that is stimulated by its ligand, hepatocyte growth factor (HGF), to induce cell growth, motility and morphogenesis. Dysregulation of c-Met function,...
3.
Xu J, Dunn M, Smith A, Tien E
Methods Mol Biol
. 2011 Oct;
795:83-107.
PMID: 21960217
Kinases are members of a major protein family targeted for drug discovery and development. Given the ubiquitous nature of many kinases as well as the broad range of pathways controlled...
4.
Ekins S, Williams A, Xu J
Drug Metab Dispos
. 2010 Sep;
38(12):2302-8.
PMID: 20843939
Drug-induced liver injury (DILI) is one of the most important reasons for drug development failure at both preapproval and postapproval stages. There has been increased interest in developing predictive in...
5.
Tang F, Xu J
Comb Chem High Throughput Screen
. 2009 Nov;
12(9):825-6.
PMID: 19938326
No abstract available.
6.
Campbell S, Lau W, Xu J
Chem Biol Interact
. 2009 Jun;
182(1):45-51.
PMID: 19560444
The existence of a porphyrin uptake transporter in hepatocytes has been hypothesized in recent years, but to date it has not been identified. While the linear tetrapyrrole bilirubin has been...
7.
Cosgrove B, King B, Hasan M, Alexopoulos L, Farazi P, Hendriks B, et al.
Toxicol Appl Pharmacol
. 2009 Apr;
237(3):317-30.
PMID: 19362101
Idiosyncratic drug hepatotoxicity represents a major problem in drug development due to inadequacy of current preclinical screening assays, but recently established rodent models utilizing bacterial LPS co-administration to induce an...
8.
Feng B, Xu J, Bi Y, Mireles R, Davidson R, Duignan D, et al.
Toxicol Sci
. 2009 Feb;
108(2):492-500.
PMID: 19223659
CP-724,714, a potent and selective orally active HER2 tyrosine kinase inhibitor, was discontinued from clinical development due to unexpected hepatotoxicity in cancer patients. Based on the clinical manifestation of the...
9.
Xu J, Henstock P, Dunn M, Smith A, Chabot J, de Graaf D
Toxicol Sci
. 2008 Jun;
105(1):97-105.
PMID: 18524759
Drug-induced liver injury (DILI) is the most common adverse event causing drug nonapprovals and drug withdrawals. Using drugs as test agents and measuring a panel of cellular phenotypes that are...
10.
Dykens J, Jamieson J, Marroquin L, Nadanaciva S, Xu J, Dunn M, et al.
Toxicol Sci
. 2008 Mar;
103(2):335-45.
PMID: 18344530
Mitochondrial toxicity is increasingly implicated in a host of drug-induced organ toxicities, including hepatotoxicity. Nefazodone was withdrawn from the U.S. market in 2004 due to hepatotoxicity. Accordingly, we evaluated nefazodone,...